Rubius Therapeutics Property, Plant & Equipment

The latest PP&E for RUBY is $2.8M as of December 2022. That compares with $87M in the prior-year period — down 96.7% year over year. Investors often review this figure alongside Rubius Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RUBY's PP&E moved from $87M to $2.8M — a 96.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rubius Therapeutics's operating scale or balance-sheet position.

A PP&E figure of $2.8M for RUBY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RUBY's PP&E ($2.8M), review year-over-year change from $87M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Rubius Therapeutics's PP&E against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.